AVXL
Anavex Life Sciences Corp.Company with tickers: AVXL
CIK
1314052
CUSIP
032797300
Shares Outstanding
92,671,758
13F Activity (30d)
146 filings
143 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $6,782,000 | USD | 2025-12-31 | 10-Q | 2026-02-09 |
| Research & Development | $4,656,000 | USD | 2025-12-31 | 10-Q | 2026-02-09 |
| Operating Income | $-6,782,000 | USD | 2025-12-31 | 10-Q | 2026-02-09 |
| Net Income | $-5,681,000 | USD | 2025-12-31 | 10-Q | 2026-02-09 |
| EPS (Basic) | $-0.06 | USD/shares | 2025-12-31 | 10-Q | 2026-02-09 |
| EPS (Diluted) | $-0.06 | USD/shares | 2025-12-31 | 10-Q | 2026-02-09 |